May 10, 2023 / 11:20PM GMT
Unidentified Analyst -
Good evening, everyone, and thank you for joining us. So today, we're delighted to be hosting Helen from Halozyme.
Questions and Answers:
Unidentified Analyst -And just wanted to go ahead and kick off with the first question. For an opportunity for Helen to speak at a high level about the business operations and driving growth through pipeline candidates that you've laid out and through portfolio diversification, through business development, I would love if you could talk about the business and give us a broad overview.
Helen I. Torley - Halozyme Therapeutics, Inc. - President, CEO & Director
Yes. Thanks for this opportunity. So Halozyme is a profitable biotech company. We are focused on bringing forward disruptive solutions that can improve the treatment experience and potentially also improve outcomes. We do this through 2 drug delivery technologies that's focused on subcutaneous delivery, and we also have a specialty pharmaceutical business as well.
When we think about our drug delivery
Trustpilot
